USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report)'s share price hit a new 52-week low on Thursday . The company traded as low as $34.76 and last traded at $35.04, with a volume of 3078 shares. The stock had previously closed at $35.43.
Analyst Ratings Changes
Several analysts have recently issued reports on USNA shares. StockNews.com cut shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, July 24th. DA Davidson decreased their price objective on shares of USANA Health Sciences from $46.00 to $38.00 and set a "neutral" rating for the company in a report on Thursday, July 25th.
Check Out Our Latest Research Report on USNA
USANA Health Sciences Stock Performance
The stock has a 50 day moving average of $38.61 and a two-hundred day moving average of $43.29. The stock has a market cap of $681.84 million, a PE ratio of 11.15, a PEG ratio of 1.20 and a beta of 0.89.
USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its earnings results on Tuesday, July 23rd. The company reported $0.54 earnings per share for the quarter, missing the consensus estimate of $0.65 by ($0.11). USANA Health Sciences had a return on equity of 11.13% and a net margin of 6.29%. The firm had revenue of $212.87 million during the quarter, compared to analyst estimates of $218.64 million. During the same period in the previous year, the company earned $0.89 earnings per share. Analysts expect that USANA Health Sciences, Inc. will post 2.5 EPS for the current fiscal year.
Insider Buying and Selling
In other USANA Health Sciences news, insider Paul A. Jones sold 6,266 shares of USANA Health Sciences stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total transaction of $240,489.08. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, insider Paul A. Jones sold 6,266 shares of the firm's stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $38.38, for a total value of $240,489.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Gilbert A. Fuller sold 674 shares of the company's stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $39.69, for a total transaction of $26,751.06. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 7,940 shares of company stock valued at $311,670. 0.33% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. CWM LLC boosted its holdings in USANA Health Sciences by 21.8% in the 1st quarter. CWM LLC now owns 1,543 shares of the company's stock valued at $75,000 after purchasing an additional 276 shares during the period. BOKF NA raised its holdings in USANA Health Sciences by 274.5% during the 1st quarter. BOKF NA now owns 2,771 shares of the company's stock worth $133,000 after purchasing an additional 2,031 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of USANA Health Sciences by 9.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company's stock valued at $284,000 after purchasing an additional 494 shares during the period. DGS Capital Management LLC lifted its stake in USANA Health Sciences by 61.8% in the first quarter. DGS Capital Management LLC now owns 7,258 shares of the company's stock valued at $352,000 after buying an additional 2,773 shares during the period. Finally, SG Americas Securities LLC bought a new position in USANA Health Sciences during the second quarter worth $340,000. Institutional investors and hedge funds own 54.25% of the company's stock.
USANA Health Sciences Company Profile
(
Get Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Featured Stories
Before you consider USANA Health Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and USANA Health Sciences wasn't on the list.
While USANA Health Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
